These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 26028417)

  • 1. [Plasma concentrations of anionic uremic toxins in hemodialysis patients and their effects on protein binding of pravastatin].
    Ichimura Y; Takamatsu H; Ideuchi H; Oda M; Takeda K; Saitoh H
    Yakugaku Zasshi; 2015; 135(6):821-8. PubMed ID: 26028417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlations between Plasma Levels of Anionic Uremic Toxins and Clinical Parameters in Hemodialysis Patients.
    Ichimura Y; Takamatsu H; Ideuchi H; Oda M; Takeda K; Saitoh H
    Yakugaku Zasshi; 2016; 136(8):1177-84. PubMed ID: 27477735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased bilirubin-binding capacity in uremic serum caused by an accumulation of furan dicarboxylic acid.
    Tsutsumi Y; Maruyama T; Takadate A; Shimada H; Otagiri M
    Nephron; 2000 May; 85(1):60-4. PubMed ID: 10773757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the adequacy parameter Kt/V(urea) reflect uremic toxin concentrations in hemodialysis patients?
    Eloot S; Van Biesen W; Glorieux G; Neirynck N; Dhondt A; Vanholder R
    PLoS One; 2013; 8(11):e76838. PubMed ID: 24236005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient removal of albumin-bound furancarboxylic acid by protein-leaking hemodialysis.
    Niwa T; Asada H; Tsutsui S; Miyazaki T
    Am J Nephrol; 1995; 15(6):463-7. PubMed ID: 8546166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia.
    Lim CF; Bernard BF; de Jong M; Docter R; Krenning EP; Hennemann G
    J Clin Endocrinol Metab; 1993 Feb; 76(2):318-24. PubMed ID: 8432774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accumulation of furancarboxylic acids in uremic serum as inhibitors of drug binding.
    Niwa T; Takeda N; Maeda K; Shibata M; Tatematsu A
    Clin Chim Acta; 1988 Apr; 173(2):127-38. PubMed ID: 3378354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of binding site of uremic toxins on human serum albumin.
    Sakai T; Takadate A; Otagiri M
    Biol Pharm Bull; 1995 Dec; 18(12):1755-61. PubMed ID: 8787801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two rapid, accurate liquid chromatography tandem mass spectrometry methods for the quantification of seven uremic toxins: An application for describing their accumulation kinetic profile in a context of acute kidney injury.
    André C; Bennis Y; Titeca-Beauport D; Caillard P; Cluet Y; Kamel S; Choukroun G; Maizel J; Liabeuf S; Bodeau S
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Sep; 1152():122234. PubMed ID: 32615535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indole 3-acetic acid, indoxyl sulfate and paracresyl-sulfate do not influence anemia parameters in hemodialysis patients.
    Bataille S; Pelletier M; Sallée M; Berland Y; McKay N; Duval A; Gentile S; Mouelhi Y; Brunet P; Burtey S
    BMC Nephrol; 2017 Jul; 18(1):251. PubMed ID: 28747155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Removal of protein-bound uraemic toxins by haemodialysis.
    Niwa T
    Blood Purif; 2013; 35 Suppl 2():20-5. PubMed ID: 23676831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced renal clearance of furancarboxylic acid, a major albumin-bound organic acid, in undialyzed uremic patients.
    Sato M; Koyama M; Miyazaki T; Niwa T
    Nephron; 1996; 74(2):419-21. PubMed ID: 8893167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring Protein Binding of Uremic Toxins in Patients with Different Stages of Chronic Kidney Disease and during Hemodialysis.
    Deltombe O; Van Biesen W; Glorieux G; Massy Z; Dhondt A; Eloot S
    Toxins (Basel); 2015 Sep; 7(10):3933-46. PubMed ID: 26426048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production.
    Itoh Y; Ezawa A; Kikuchi K; Tsuruta Y; Niwa T
    Anal Bioanal Chem; 2012 Jun; 403(7):1841-50. PubMed ID: 22447217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accumulation of indoxyl sulfate, an inhibitor of drug-binding, in uremic serum as demonstrated by internal-surface reversed-phase liquid chromatography.
    Niwa T; Takeda N; Tatematsu A; Maeda K
    Clin Chem; 1988 Nov; 34(11):2264-7. PubMed ID: 3141084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influences of haemodialysis on the binding sites of human serum albumin: possibility of an efficacious administration plan using binding inhibition.
    Nishio T; Takamura N; Nishii R; Tokunaga J; Yoshimoto M; Kawai K
    Nephrol Dial Transplant; 2008 Jul; 23(7):2304-10. PubMed ID: 18390890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of renal transplantation on a major endogenous ligand retained in uremic serum.
    Mabuchi H; Nakahashi H; Hamajima T; Aikawa I; Oka T
    Am J Kidney Dis; 1989 Jan; 13(1):49-54. PubMed ID: 2643310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intradialytic removal of protein-bound uraemic toxins: role of solute characteristics and of dialyser membrane.
    Lesaffer G; De Smet R; Lameire N; Dhondt A; Duym P; Vanholder R
    Nephrol Dial Transplant; 2000 Jan; 15(1):50-7. PubMed ID: 10607767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is 3-Carboxy-4-methyl-5-propyl-2-furanpropionate (CMPF) a Clinically Relevant Uremic Toxin in Haemodialysis Patients?
    Luce M; Bouchara A; Pastural M; Granjon S; Szelag JC; Laville M; Arkouche W; Fouque D; Soulage CO; Koppe L
    Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29783628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of organic anion transporters in the efflux of uremic toxins across the blood-brain barrier.
    Deguchi T; Isozaki K; Yousuke K; Terasaki T; Otagiri M
    J Neurochem; 2006 Feb; 96(4):1051-9. PubMed ID: 16445853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.